Igc Pharma, Inc. (IGC) Stock Price & Analysis
Igc Pharma, Inc. (IGC) fell 4.68% to USD 0.29 as of June 10, 2026 at 00:25 UTC, according to Nexqual real-time market data.
IGC last closed at USD 0.3; the session ranged USD 0.28–0.3 on volume of 1,287,508 shares. Market capitalization is $28.53M, with a 52-week range of USD 0.24–0.5 (ASE). Source: Nexqual, June 10, 2026 at 00:25 UTC.
Key Statistics (as of June 10, 2026 at 00:25 UTC)
| Price | USD 0.29 |
|---|---|
| Change | ▼ 4.68% (down) |
| Previous Close | USD 0.3 |
| Open | USD 0.29 |
| Day Range | USD 0.28 – 0.3 |
| 52-Week Range | USD 0.24 – 0.5 |
| Volume | 1,287,508 shares |
| Market Cap | $28.53M |
| Exchange | ASE |
Technical Analysis (IGC)
Nexqual's technical model rates IGC "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.47 (neutral) |
| vs SMA50 | Below (USD 0.3) |
| MACD | -0 (negative) |
Analyst Ratings (IGC)
Wall Street analysts rate IGC "Strong Buy" based on 2 analysts, with a mean price target of USD 4.25 (range USD 3–5.5), per Nexqual as of June 10, 2026 at 00:25 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 4.25 |
| High Target | USD 5.5 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (IGC)
| EPS Estimate | USD -0.02 |
|---|---|
| Revenue Estimate | $164,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.02 vs est -0.02 ▲ beat |
| 2025-03-31 | USD -0.01 vs est -0.02 ▲ beat |
| 2024-12-31 | USD -0.02 vs est -0.03 ▲ beat |
| 2024-09-30 | USD -0.02 vs est -0.03 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financials & Fundamentals (IGC)
| Total Revenue | $1.11M |
|---|---|
| Revenue Growth (YoY) | -3.90% |
| Gross Margin | +46.20% |
| Operating Margin | -775.39% |
| Profit Margin | +0.00% |
| ROE | -83.34% |
| Debt / Equity | 14.98 |
| Current Ratio | 1.32 |
| Total Cash | $235,000 |
| Total Debt | $917,000 |
| Free Cash Flow | $-2.52M |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Financial Health Score (IGC)
Nexqual rates Igc Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:25 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $235K cash, no debt |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -83%, ROA -50.3% |
Ownership (IGC)
| Insider Ownership | +9.68% |
|---|---|
| Institutional Ownership | +22.51% |
| Shares Outstanding | 100.09M |
| Float | 90.22M |
| Short % of Float | +2.27% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
Leadership (IGC)
Igc Pharma, Inc. is led by Ram Mukunda (age 66), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 00:25 UTC.
| Founder, President, CEO & Director | Ram Mukunda (age 66) |
|---|---|
| VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director | Claudia Grimaldi (age 53) |
| Director of Operations | Benysh Qureshi Esq. |
| Director of Accounting & Senior Director | Rohit Goel (age 31) |
Major Backers & Investors (IGC)
Notable institutional backers of Igc Pharma, Inc. include Fidelity, AdvisorShares Trust-AdvisorShares Psychedelics ETF, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 00:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.08% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 1.42% |
| Renaissance Technologies | 1.22% |
| Susquehanna International Group, LLP | 0.31% |
| Lawood & Co | 0.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.67% |
| Geode Capital | 2.64% |
| BlackRock | 1.78% |
| State Street | 0.51% |
| Northern Trust | 0.29% |
Source: Nexqual, June 10, 2026 at 00:25 UTC.
From Igc Pharma, Inc.'s Latest SEC 10-K Filing (filed 2025-06-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Our IP strategy is centered on securing exclusive rights to proprietary technologies, inventions, and product candidates through the development, acquisition, and licensing of patents and related protections both in the United States and internationally.   We actively seek to protect our innovations by filing patent applications that cover novel methods, compositions, and uses associated with our investigational drug candidates, formulations, and related technologies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OGEN | Oragenics Inc. | USD 0.6 | ▲ 1.69% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| XXII | 22nd Century Group, Inc | USD 0.37 | ▼ 21.17% |
| CVSI | CV Sciences, Inc. | USD 0.03 | ▼ 3.33% |
| PRPO | Precipio, Inc. | USD 23.32 | ▼ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:25 UTC. This page is informational and not investment advice.